- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00444925
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
keskiviikko 4. maaliskuuta 2015 päivittänyt: Pfizer
12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
Tutkimuksen yleiskatsaus
Tila
Valmis
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
1712
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
-
Antwerpen, Belgia, 2020
- Pfizer Investigational Site
-
Bruxelles, Belgia, 1070
- Pfizer Investigational Site
-
Kortrijk, Belgia, 8500
- Pfizer Investigational Site
-
Tessenderlo, Belgia, 3980
- Pfizer Investigational Site
-
-
-
-
BA
-
Salvador, BA, Brasilia, 40420-000
- Pfizer Investigational Site
-
-
RJ
-
Rio de Janeiro, RJ, Brasilia, CEP 20551-030
- Pfizer Investigational Site
-
-
RS
-
Porto Alegre, RS, Brasilia, 90020-090
- Pfizer Investigational Site
-
Porto Alegre, RS, Brasilia, 90470-340
- Pfizer Investigational Site
-
-
SP
-
Campinas, SP, Brasilia, 13084-882
- Pfizer Investigational Site
-
São Paulo, SP, Brasilia, 04262-000
- Pfizer Investigational Site
-
São Paulo, SP, Brasilia, 04039-901
- Pfizer Investigational Site
-
-
-
-
-
Puerto Montt, Chile, 5480000
- Pfizer Investigational Site
-
Santiago, Chile
- Pfizer Investigational Site
-
-
VI Región
-
Rancagua, VI Región, Chile, 2820945
- Pfizer Investigational Site
-
-
-
-
-
Alajuela, Costa Rica
- Pfizer Investigational Site
-
Cartago, Costa Rica
- Pfizer Investigational Site
-
San Jose, Costa Rica
- Pfizer Investigational Site
-
-
-
-
-
Madrid, Espanja, 28046
- Pfizer Investigational Site
-
Valencia, Espanja, 46010
- Pfizer Investigational Site
-
-
Madrid
-
Getafe, Madrid, Espanja, 28905
- Pfizer Investigational Site
-
-
Vizcaya
-
Bilbao, Vizcaya, Espanja, 48013
- Pfizer Investigational Site
-
-
-
-
-
Cape Town, Etelä-Afrikka, 8001
- Pfizer Investigational Site
-
Pretoria, Etelä-Afrikka, 0083
- Pfizer Investigational Site
-
-
Free State
-
Bloemfontein, Free State, Etelä-Afrikka, 9300
- Pfizer Investigational Site
-
-
Gauteng
-
Vosloorus, Gauteng, Etelä-Afrikka, 1475
- Pfizer Investigational Site
-
-
Gauteng Province
-
Parktown, Gauteng Province, Etelä-Afrikka, 2193
- Pfizer Investigational Site
-
-
Kwa Zulu Natal
-
Durban, Kwa Zulu Natal, Etelä-Afrikka, 4001
- Pfizer Investigational Site
-
Pietermaritzburg, Kwa Zulu Natal, Etelä-Afrikka, 3201
- Pfizer Investigational Site
-
-
-
-
-
Hong Kong, Hong Kong
- Pfizer Investigational Site
-
Shatin, Hong Kong
- Pfizer Investigational Site
-
-
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, Intia, 500 001
- Pfizer Investigational Site
-
Hyderabad, Andhra Pradesh, Intia, 500 082
- Pfizer Investigational Site
-
-
Karnataka
-
Bangalore, Karnataka, Intia, 560 034
- Pfizer Investigational Site
-
-
Rajasthan
-
Jaipur, Rajasthan, Intia, 302 004
- Pfizer Investigational Site
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Intia, 632 004
- Pfizer Investigational Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Intia, 226003
- Pfizer Investigational Site
-
-
-
-
-
Latina, Italia, 04100
- Pfizer Investigational Site
-
Padova, Italia, 35128
- Pfizer Investigational Site
-
Siena, Italia, 53100
- Pfizer Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2V 4R6
- Pfizer Investigational Site
-
Edmonton, Alberta, Kanada, T5H 3V9
- Pfizer Investigational Site
-
-
British Columbia
-
Victoria, British Columbia, Kanada, V8V 3N1
- Pfizer Investigational Site
-
-
New Brunswick
-
Saint John, New Brunswick, Kanada, E2L 3J8
- Pfizer Investigational Site
-
-
Ontario
-
Kitchener, Ontario, Kanada, N2N 2B9
- Pfizer Investigational Site
-
Toronto, Ontario, Kanada, M4N 3M5
- Pfizer Investigational Site
-
Toronto, Ontario, Kanada, M6A 3B5
- Pfizer Investigational Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 1N8
- Pfizer Investigational Site
-
Montreal, Quebec, Kanada, H3S 1Z1
- Pfizer Investigational Site
-
Montréal, Quebec, Kanada, H2X 3J4
- Pfizer Investigational Site
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Pfizer Investigational Site
-
-
-
-
Cundinamarca
-
Bogota, Cundinamarca, Kolumbia
- Pfizer Investigational Site
-
Bogota, Cundinamarca, Kolumbia
- Pfizer Investigational Site
-
-
-
-
-
Daegu, Korean tasavalta, 705-718
- Pfizer Investigational Site
-
Seoul, Korean tasavalta, 120-752
- Pfizer Investigational Site
-
Seoul, Korean tasavalta, 136-705
- Pfizer Investigational Site
-
Seoul, Korean tasavalta, 137-040
- Pfizer Investigational Site
-
Seoul, Korean tasavalta, 100-380
- Pfizer Investigational Site
-
-
Korea
-
Seoul, Korea, Korean tasavalta, 110-744
- Pfizer Investigational Site
-
-
-
-
-
Rio, Patras, Kreikka, 26500
- Pfizer Investigational Site
-
Thessaloniki, Kreikka, 56403
- Pfizer Investigational Site
-
-
Attiki
-
Athens, Attiki, Kreikka, 10552
- Pfizer Investigational Site
-
-
Ipiros
-
Ioannina, Ipiros, Kreikka, 45001
- Pfizer Investigational Site
-
-
-
-
-
Kuala Lumpur, Malesia, 59100
- Pfizer Investigational Site
-
-
Selangor
-
Batu Caves, Selangor, Malesia, 68100
- Pfizer Investigational Site
-
-
-
-
-
Bergen, Norja, 5005
- Pfizer Investigational Site
-
Hamar, Norja, 2317
- Pfizer Investigational Site
-
Lysaker, Norja, 1366
- Pfizer Investigational Site
-
Oslo, Norja, NO-0257
- Pfizer Investigational Site
-
Oslo, Norja, 0264
- Pfizer Investigational Site
-
Sandnes, Norja, 4313
- Pfizer Investigational Site
-
-
-
-
-
Lima, Peru, L27
- Pfizer Investigational Site
-
-
Lima
-
Surco, Lima, Peru, L33
- Pfizer Investigational Site
-
-
-
-
-
Bialystok, Puola, 15-950
- Pfizer Investigational Site
-
Bydgoszcz, Puola, 85-168
- Pfizer Investigational Site
-
Lodz, Puola, 91-463
- Pfizer Investigational Site
-
Szczecin, Puola, 70-11
- Pfizer Investigational Site
-
Warszawa, Puola, 02-507
- Pfizer Investigational Site
-
-
-
-
-
Arad, Romania, 310175
- Pfizer Investigational Site
-
Bucuresti, Romania, 041345
- Pfizer Investigational Site
-
Bucuresti, Romania, 050653
- Pfizer Investigational Site
-
Sibiu, Romania, 550245
- Pfizer Investigational Site
-
Timisoara, Romania, 300736
- Pfizer Investigational Site
-
-
-
-
-
Huskvarna, Ruotsi, 561 36
- Pfizer Investigational Site
-
Lulea, Ruotsi, 97180
- Pfizer Investigational Site
-
Malmo, Ruotsi, 205 02
- Pfizer Investigational Site
-
Skovde, Ruotsi, 541 30
- Pfizer Investigational Site
-
Stockholm, Ruotsi
- Pfizer Investigational Site
-
-
-
-
-
Ahaus, Saksa, 41683
- Pfizer Investigational Site
-
Alzey, Saksa, 55232
- Pfizer Investigational Site
-
Berlin, Saksa, 10787
- Pfizer Investigational Site
-
Berlin, Saksa, 13125
- Pfizer Investigational Site
-
Berlin, Saksa, 13347
- Pfizer Investigational Site
-
Karlsruhe, Saksa, 76199
- Pfizer Investigational Site
-
Krumbach, Saksa, 86381
- Pfizer Investigational Site
-
Leipzig, Saksa, 04109
- Pfizer Investigational Site
-
Leipzig, Saksa, 04105
- Pfizer Investigational Site
-
Marburg, Saksa, 35039
- Pfizer Investigational Site
-
Muelheim a.d. Ruhr, Saksa, 45468
- Pfizer Investigational Site
-
Muenchen, Saksa, 81241
- Pfizer Investigational Site
-
Muenchen, Saksa, 81925
- Pfizer Investigational Site
-
Rosenheim, Saksa, 83022
- Pfizer Investigational Site
-
-
-
-
-
Singapore, Singapore, 119074
- Pfizer Investigational Site
-
Singapore, Singapore, 229899
- Pfizer Investigational Site
-
-
-
-
-
Frauenfeld, Sveitsi, CH-8500
- Pfizer Investigational Site
-
Luzern 16, Sveitsi, CH-6000
- Pfizer Investigational Site
-
-
-
-
-
Hualien, Taiwan, 970
- Pfizer Investigational Site
-
Taichung City, Taiwan, 40705
- Pfizer Investigational Site
-
Taipei, Taiwan, 100
- Pfizer Investigational Site
-
Taipei, Taiwan
- Pfizer Investigational Site
-
-
Kaohsiung
-
Niao-Sung Hsiang, Kaohsiung, Taiwan, 833
- Pfizer Investigational Site
-
-
-
-
-
Aalborg, Tanska, 9100
- Pfizer Investigational Site
-
Aarhus N, Tanska, 8200
- Pfizer Investigational Site
-
Glostrup, Tanska, 2600
- Pfizer Investigational Site
-
Herlev, Tanska, 2730
- Pfizer Investigational Site
-
Kolding, Tanska, 6000
- Pfizer Investigational Site
-
Nykoebing Falster, Tanska, 4800
- Pfizer Investigational Site
-
Roskilde, Tanska, 4000
- Pfizer Investigational Site
-
-
-
-
-
Hradec Kralove, Tšekin tasavalta, 500 02
- Pfizer Investigational Site
-
Jablonec nad Nisou, Tšekin tasavalta, 466 60
- Pfizer Investigational Site
-
Jindrichuv Hradec, Tšekin tasavalta, 377 38
- Pfizer Investigational Site
-
Ostrava, Tšekin tasavalta, 708 52
- Pfizer Investigational Site
-
Praha 8, Tšekin tasavalta, 180 00
- Pfizer Investigational Site
-
-
-
-
-
Chernivtsi, Ukraina, 58002
- Pfizer Investigational Site
-
Kharkiv, Ukraina, 61037
- Pfizer Investigational Site
-
Kyiv, Ukraina, 04053
- Pfizer Investigational Site
-
Odessa, Ukraina, 65000
- Pfizer Investigational Site
-
Zaporizhzhia, Ukraina, 69000
- Pfizer Investigational Site
-
-
-
-
-
Debrecen, Unkari, 4026
- Pfizer Investigational Site
-
Nyiregyhaza, Unkari, 4400
- Pfizer Investigational Site
-
Szeged, Unkari, 6725
- Pfizer Investigational Site
-
Szentes, Unkari, 6600
- Pfizer Investigational Site
-
-
-
-
-
Moscow, Venäjän federaatio, 101000
- Pfizer Investigational Site
-
Moscow, Venäjän federaatio, 115516
- Pfizer Investigational Site
-
Moscow, Venäjän federaatio, 117815
- Pfizer Investigational Site
-
Rostov-on-Don, Venäjän federaatio, 344022
- Pfizer Investigational Site
-
-
Russia
-
Moscow, Russia, Venäjän federaatio, 105425
- Pfizer Investigational Site
-
St. Petersburg, Russia, Venäjän federaatio
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Homewood, Alabama, Yhdysvallat, 35209
- Pfizer Investigational Site
-
Huntsville, Alabama, Yhdysvallat, 35801
- Pfizer Investigational Site
-
Mobile, Alabama, Yhdysvallat, 36608
- Pfizer Investigational Site
-
-
California
-
Carmichael, California, Yhdysvallat, 95608
- Pfizer Investigational Site
-
Orangevale, California, Yhdysvallat, 95662
- Pfizer Investigational Site
-
San Diego, California, Yhdysvallat, 92103-6204
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80012
- Pfizer Investigational Site
-
-
Connecticut
-
Waterbury, Connecticut, Yhdysvallat, 06708
- Pfizer Investigational Site
-
-
Florida
-
Miami, Florida, Yhdysvallat, 33186
- Pfizer Investigational Site
-
Wellington, Florida, Yhdysvallat, 33414
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30342
- Pfizer Investigational Site
-
-
Idaho
-
Coeur D Alene, Idaho, Yhdysvallat, 83814
- Pfizer Investigational Site
-
Sandpoint, Idaho, Yhdysvallat, 83864
- Pfizer Investigational Site
-
-
Illinois
-
Aurora, Illinois, Yhdysvallat, 60504
- Pfizer Investigational Site
-
-
Iowa
-
West Des Moines, Iowa, Yhdysvallat, 50266
- Pfizer Investigational Site
-
-
Kansas
-
Newton, Kansas, Yhdysvallat, 67114
- Pfizer Investigational Site
-
-
Louisiana
-
Shrevport, Louisiana, Yhdysvallat, 71106
- Pfizer Investigational Site
-
-
Massachusetts
-
Watertown, Massachusetts, Yhdysvallat, 02472
- Pfizer Investigational Site
-
-
Minnesota
-
Chaska, Minnesota, Yhdysvallat, 55318
- Pfizer Investigational Site
-
-
New Jersey
-
Lawrenceville, New Jersey, Yhdysvallat, 08648
- Pfizer Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, Yhdysvallat, 87109
- Pfizer Investigational Site
-
-
New York
-
Garden City, New York, Yhdysvallat, 11530
- Pfizer Investigational Site
-
Mineola, New York, Yhdysvallat, 11501
- Pfizer Investigational Site
-
-
North Carolina
-
Burlington, North Carolina, Yhdysvallat, 27215
- Pfizer Investigational Site
-
Concord, North Carolina, Yhdysvallat, 28025
- Pfizer Investigational Site
-
Huntersville, North Carolina, Yhdysvallat, 28078
- Pfizer Investigational Site
-
-
Ohio
-
Dayton, Ohio, Yhdysvallat, 45439
- Pfizer Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, Yhdysvallat, 18106
- Pfizer Investigational Site
-
Allentown, Pennsylvania, Yhdysvallat, 18103
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15212
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15213-3180
- Pfizer Investigational Site
-
-
Rhode Island
-
East Providence, Rhode Island, Yhdysvallat, 02914
- Pfizer Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Yhdysvallat, 29425
- Pfizer Investigational Site
-
Columbia, South Carolina, Yhdysvallat, 29201
- Pfizer Investigational Site
-
-
Tennessee
-
Kingsport, Tennessee, Yhdysvallat, 37660
- Pfizer Investigational Site
-
Milan, Tennessee, Yhdysvallat, 38358
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77024
- Pfizer Investigational Site
-
-
Utah
-
Provo, Utah, Yhdysvallat, 84604
- Pfizer Investigational Site
-
-
Virginia
-
Chesapeake, Virginia, Yhdysvallat, 23320
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98104
- Pfizer Investigational Site
-
-
Wisconsin
-
Menomonee Falls, Wisconsin, Yhdysvallat, 53051
- Pfizer Investigational Site
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
- Adult overactive bladder (OAB) patients who present with OAB symptoms, including urinary frequency >= 8 per day and urgency urinary incontinence >=1 per day
Exclusion Criteria:
- Patients with conditions that would contraindicate for fesoterodine use, e.g, hypersensitivity to the active substance (fesoterodine) or to peanut or soya or any of the excipients, urinary retention, and gastric retention.
- Patients with significant hepatic and renal disease or other significant unstable diseases.
- OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Fesoterodiini
Tabletit
|
4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
|
|
Placebo Comparator: Placebo
Tablets and capsules
|
once daily (OD)for 12 weeks
|
|
Active Comparator: Tolterodine
Capsules
|
4 mg once daily (OD) for 12 weeks
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).
Aikaikkuna: Baseline, Week 12
|
UUI per 24 hours: total number of micturitions with Urinary Sensation Scale (USS) of 5 divided by total number of diary days collected at visit.
USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change: mean at observation minus mean at baseline.
|
Baseline, Week 12
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 1 and Week 4.
Aikaikkuna: Baseline, Week 1, Week 4
|
UUI episodes per 24 hours calculated as total number of micturitions with Urinary Sensation Scale (USS) of 5 divided by total number of diary days collected at visit.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4
|
|
Percent Change From Baseline of UUI Episodes Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
UUI episodes per 24 hours calculated as total number of micturitions with USS of 5 in diary.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as UUI episodes per 24 hours at observation divided by baseline number of UUI episodes per 24 hours, multiplied by 100.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Voided Volume Per Micturition.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Mean voided volume calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume greater than 0 in the 3-day diary at that visit.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Number of Micturitions Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
The mean number of micturitions was calculated as the sum of all micturitions divided by the total number of diary days collected at that visit.
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Percent Change From Baseline of Micturitions Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Percent change of micturitions per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (ie, 100% *(Week 12 or 4 - baseline)/baseline).
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Mean number of nocturnal micturitions per 24 hours was calculated as the sum of all micturitions divided by the total number of diary days collected at that visit.
Nocturnal (Bedtime) was defined as the time the subject went to bed until he/she arose to start the next day.
|
Baseline, Week 1, Week 4, Week 12
|
|
Percent Change From Baseline of Nocturnal Micturitions Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Percent change of nocturnal micturitions per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (ie, 100% *(Week 12 or 4 - baseline)/baseline). Nocturnal (Bedtime) was defined as the time the subject went to bed until he/she arose to start the next day.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Mean number urgency episodes (USS rating >= to 3 in diary) per 24 hours calculated as sum of all micturitions divided by total number of diary days collected at visit.
USS: 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Percent Change From Baseline of Urgency Episodes Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Percent change of urgency episodes (USS rating >= to 3 in diary) per 24 hours calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100.
USS: 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Number of Severe Urgency Episodes Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Mean number of severe urgency episodes (USS rating >= to 4 in diary ) per 24 hours: sum of all micturitions divided by total number of diary days collected at that visit.
USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Percent Change From Baseline of Severe Urgency Episodes Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Percent change calculated as change in severe urgency episodes (USS rating >= to 4 in diary ) per 24 hours at that visit divided by the baseline number of severe urgency episodes per 24 hours, multiplied by 100.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean USS Rating Per Micturition Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Mean USS rating calculated as the sum of rating scores on USS per 24 hours divided by the mean number of micturitions per 24 hours at that visit.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Frequency-Urgency Sum (Formerly Known as Urinary Sensations Scale Sum in Protocol) Per 24 Hours.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Frequency-Urgency Sum rating per 24 hours calculated as mean rating scores on the USS multiplied by the mean number of micturitions per 24 hours at that visit.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Patient Perception of Bladder Condition (PPBC).
Aikaikkuna: Baseline, Week 1, Week, 4, Week 12
|
Number of subjects in 4-point category: >= to 2 points improvement [major improvement]; 1 point improvement [minor improvement]; no change; deterioration, based on PPBC score (rated on 6-point scale: 1=no problems at all; 6=many severe problems).
Score change: score at observation minus score at baseline; re-scaled to 4-point categorical variables.
|
Baseline, Week 1, Week, 4, Week 12
|
|
Change From Baseline in Urgency Perception Scale (UPS). UPS Equals Patient Perception of Urgency Scale (PPUS) in Protocol.
Aikaikkuna: Baseline, Week 1, Week 4, Week 12
|
Number of subjects in 3-point category: improvement [>=1-point improvement]; no change; deterioration [>=1-point decrease], based on UPS score (rated on 3-point scale: 1=not able to hold urine; 3=able to finish what I am doing).
Score change calculated as score at observation minus score at baseline; re-scaled to 3-point categorical variables.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score at Week 12 (End of Treatment).
Aikaikkuna: Baseline, Week 12
|
Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48.
Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/by raw score range * 100].
Higher transformed scores indicative of greater symptom bother.
Negative change in Symptom Bother score indicates improvement.
Change calculated as score at observation minus score at baseline.
|
Baseline, Week 12
|
|
Change From Baseline in OAB-q: Health Related Quality of Life (HRQL) at Week 12 (End of Treatment).
Aikaikkuna: Baseline, Week 12
|
HRQL domain and total raw score derived as sum of scores (6-point scale: 1=not at all/none of the time; 6=a very great deal/all of the time).
Transformed score (Total HRQL or domain)=[(Highest possible raw score-Actual total raw score)/Raw score range]x100.
Higher transformed scores indicative of better HRQL.
Positive change in HRQL scores indicates improvement.
Change: score at observation minus score at baseline.
|
Baseline, Week 12
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Yleiset julkaisut
- Wagg AS, Herschorn S, Carlsson M, Fernet M, Oelke M. A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder. J Comp Eff Res. 2022 Sep;11(13):919-925. doi: 10.2217/cer-2022-0041. Epub 2022 Jul 26.
- Corcos J, Angulo JC, Garely AD, Carlsson M, Gong J, Guan Z; Fesoterodine Assessment and Comparison Versus Tolterodine (FACT) Study Group. Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Curr Med Res Opin. 2011 May;27(5):1059-65. doi: 10.1185/03007995.2011.565044. Epub 2011 Mar 23.
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Sunnuntai 1. huhtikuuta 2007
Ensisijainen valmistuminen (Todellinen)
Tiistai 1. heinäkuuta 2008
Opintojen valmistuminen (Todellinen)
Tiistai 1. heinäkuuta 2008
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Tiistai 6. maaliskuuta 2007
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Keskiviikko 7. maaliskuuta 2007
Ensimmäinen Lähetetty (Arvio)
Torstai 8. maaliskuuta 2007
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Tiistai 24. maaliskuuta 2015
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Keskiviikko 4. maaliskuuta 2015
Viimeksi vahvistettu
Sunnuntai 1. maaliskuuta 2015
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Urologiset sairaudet
- Virtsarakon sairaudet
- Alempien virtsateiden oireet
- Urologiset ilmenemismuodot
- Virtsarakko, yliaktiivinen
- Huumeiden fysiologiset vaikutukset
- Neurotransmitterit
- Farmakologisen vaikutuksen molekyylimekanismit
- Muskariiniantagonistit
- Kolinergiset antagonistit
- Kolinergiset aineet
- Urologiset aineet
- Tolterodiinitartraatti
- Fesoterodiini
Muut tutkimustunnusnumerot
- A0221008
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .